Stanford Medicine Children’s Health provides comprehensive pediatric cancer care through its Bass Center for Childhood Cancer and Blood Diseases, which is nationally ranked by U.S. News & World Report for pediatric cancer. The center is part of the National Cancer Institute-designated Stanford Cancer Institute and participates in the Children’s Oncology Group, making all patients eligible for the national cooperative group’s treatment protocols. The majority of patients choose to enroll in one of the center’s dozens of open clinical trials, including several offered only at Stanford and others made available through a partnership with Memphis, Tenn.-based St. Jude Children’s Research Hospital. Many of these trials aren’t offered anywhere else in Northern California. The Bass Center runs dedicated programs for adolescent and young adult cancer, brain tumors, bone tumors and soft-tissue sarcoma, leukemia and lymphoma, rare tumors such as neuroblastoma, retinoblastoma, Wilms tumor and germ cell tumors, and cancer predisposition syndromes. The program also includes a dedicated clinic for the long-term follow-up of pediatric cancer patients, addressing late effects that can arise after treatment. In 2026, Stanford Medicine launched a series of advanced pediatric cancer treatments and facilities, highlighted by the opening of the world’s first ultracompact proton therapy center.
